The mechanisms underlying adiposome-mediated protection of NSCLC cells (H460)
碩士 === 國立中興大學 === 生命科學系所 === 106 === The multiple drug resistance of lung cancer has been a major obstacle in the treatment of lung cancer. Rosiglitazone (ROSI) is a PPARγ agonist and clinically has been used to treat diabetes and breast cancer. Results from our early studies however, had shown that...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2018
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/9249vt |